Cidara Therapeutics has been awarded a contract from the U.S. Department of Health and Human Services (HHS) valued at up to $339 million, aimed at bolstering onshore manufacturing and advancing clinical research for its investigational antiviral biologic intended to prevent both seasonal and pandemic influenza infections. This significant funding underscores the growing emphasis on preparedness against viral outbreaks, particularly in light of recent global health crises.
The BARDA award not only facilitates the scaling of production capabilities but also enhances the clinical development pathway for Cidara’s candidate, which could play a crucial role in mitigating the impact of flu seasons and potential pandemics. As regulatory bodies and public health organizations prioritize innovative solutions to infectious diseases, this investment positions Cidara at the forefront of antiviral development, potentially influencing market dynamics and competitive strategies within the pharmaceutical sector.
Use the database as your supply chain compass →
